Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
70 hedge funds and large institutions have $370M invested in Bellicum Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 7 closing their positions.
62% more capital invested
Capital invested by funds: $229M → $370M (+$141M)
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
4% more funds holding
Funds holding: 67 → 70 (+3)
34% less call options, than puts
Call options by funds: $815K | Put options by funds: $1.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.13M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.44M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.13M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$2.67M |
| 2 |
JP Morgan Chase
New York
|
-$2.09M |
| 3 |
QF
QVT Financial
New York
|
-$2.05M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.1M |
| 5 |
Goldman Sachs
New York
|
-$838K |
BLCM Hedge Fund Activity: Q3 2016 in Review
70 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q3 2016, worth a combined $370M — up 62% from $229M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BLCM positions and 7 closed out — a net gain of 3 holders — while 27 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $18.1M. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $2.67M sold.
- 70 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q3 2016, up from 67 in Q2 2016.
- Funds reported $370M of Bellicum Pharmaceuticals, Inc. stock for Q3 2016, up 62% quarter-over-quarter.
- 10 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q3 2016 and 7 closed out, a net change of +3 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q3 2016 was Fidelity Investments, an estimated $18.1M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q3 2016 was Foresite Capital Management III, an estimated $2.67M sold.
Based on aggregated 13F filings for Q3 2016.